)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Inhibrx Biosciences (INBX) investor relations material
Inhibrx Biosciences Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary12 Aug, 2025
Executive summary
Completed spin-off and sale of INBRX-101 to Sanofi in May 2024, resulting in a stand-alone, publicly traded company focused on ozekibart (INBRX-109) and INBRX-106 clinical programs, both in active trials with key data readouts expected in late 2025.
Financial highlights
Revenue for Q2 2025 was $1.3 million, up from $0.1 million in Q2 2024, mainly from new licensing agreements.
Net loss for Q2 2025 was $28.7 million, compared to net income of $1.9 billion in Q2 2024, which included a $2.0 billion one-time gain from the INBRX-101 transaction.
Research and development expenses decreased to $22.3 million in Q2 2025 from $67.6 million in Q2 2024.
General and administrative expenses dropped to $6.4 million in Q2 2025 from $93.4 million in Q2 2024.
Cash and cash equivalents were $186.6 million as of June 30, 2025, down from $216.5 million at March 31, 2025.
Outlook and guidance
Existing cash is expected to fund operations for at least the next 12 months.
Full enrollment completed for ozekibart (INBRX-109) Phase 2 trial in chondrosarcoma; data readout expected by late October 2025.
Initial Phase 2 data for INBRX-106 in head and neck cancer and interim data in lung cancer expected in Q4 2025.
Anticipates increased R&D expenses as clinical programs advance, with key data from ongoing trials expected in late 2025.
Given current burn, when does cash run out?
What is the status of ozekibart unblinding?
What is the current long-term debt balance?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Inhibrx Biosciences earnings date
Q3 202514 Nov, 2025
Next Inhibrx Biosciences earnings date
Q3 202514 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Inhibrx Biosciences Inc. is a clinical-stage biotechnology company focused on developing biologic therapeutic candidates. The company's work is centered on leveraging its proprietary protein engineering platforms to design and develop therapies aimed at treating serious and life-threatening conditions. Inhibrx's pipeline includes multiple candidates that target various pathways involved in cancer and other critical diseases, with several programs in clinical trials. Inhibrx Biosciences is headquartered in La Jolla, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage